Kikuchi-Fujimoto disease following SARS CoV2 vaccination: Case report

• Main Authors: Hussam Al Soub, Wanis Ibrahim, Muna Al Maslamani, Gawahir A. Ali, Waseem Ummer, Ala’ Abu-Dayeh
• Format: Article
• Language: English
• Published: Elsevier 2021-01-01
• Series: IDCases
• Subjects: SARS CoV 2; Kikuchi; Fujimoto; Lymphadenopathy; COVID 19 vaccine
• Online Access: http://www.sciencedirect.com/science/article/pii/S2214250921002092

Kikuchi's disease (KD) also known as Kikuchi-Fujimoto disease (KFD), or histiocytic necrotizing lymphadenitis was first described in 1972 independently by Kikuchi and Fujimoto et al. It is a benign self-limited condition of unknown etiology which usually presents with cervical lymphadenopathy or fever of unknown origin. The diagnosis of KFD is based on histopathologic examination of the involved lymph node, showing the presence of well-defined necrosis without granulocytic cells. There is no special treatment for KFD. However non-steroidal anti-inflammatory drugs or corticosteroids are required occasionally to control the associated systemic manifestations. The outcome of the disease is usually favorable with resolution of symptoms in most cases within one to four months. We report a case of Kikuchi-Fujimoto disease that occurred in a young Qatari male patient 10 days following receiving the first dose of BNT162b2 vaccine. Diagnosis was established by lymph node biopsy and recovery was complete after 10 days.